Physician profile
Nirav Patel
NPI 1477058360
$5,833.18
in general payments reported to CMS, 2019-2025
13 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what 76% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,137 · 2024: $2,012 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,788 · Food and Beverage: $2,546 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,787.68 |
| Food and Beverage | $2,545.50 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,124.79 | 2023-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, General - Pain Management |
| Abbott Laboratories | $1,089.44 | 2025 | Proclaim |
| Relievant Medsystems, INC. | $534.55 | 2023 | Intracept |
| Globus Medical, INC. | $297.64 | 2025 | Senza |
| Medtronic, INC. | $213.18 | 2024 | Cardioblate |
| Nevro Corp. | $167.37 | 2023 | Senza |
| Saluda Medical Americas, INC. | $147.69 | 2023 | Evoke Scs |
| Mml US, INC. | $131.76 | 2024 | Reactiv8 |
| Innovation Technologies INC | $49.71 | 2025 | Irrisept |
| Averitas Pharma INC. | $27.92 | 2024 | Qutenza |
| Spr Therapeutics, INC | $20.02 | 2025 | Sprint Pns System |
| Stryker Corporation | $15.08 | 2023 | Spinejack |
| Almatica Pharma LLC | $14.03 | 2023 | Gralise |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.